Taxane chemotherapy is unable to sensitize prostate cancer to immune checkpoint inhibitors, resulting in another negative trial with immunotherapy in prostate cancer,” said Andrea Necchi, MD.

Global Phase 3 TRANSCEND study will evaluate the efficacy and safety of felzartamab, as compared to placebo, in adults with late AMRAMR is a ...

In a late-stage trial of patients with multiple types of blood cancer, Orca Bio’s allogeneic T-cell immunotherapy doubled the ...

BioCity Biopharmaceuticals and MSD have signed a clinical trial partnership agreement to assess BC3195 in conjunction with ...

Despite finally winning a hard-fought FDA approval for its chronic kidney disease (CKD) anemia drug Vafseo last year, Akebia Therapeutics’ endgame remains focused on pushing the therapy into a wide | ...

Gilead is set to launch a Phase III trial of its once-yearly lenacapavir pre-exposure prophylaxis (PrEP) for human ...

MSD and Daiichi Sankyo have revealed some of the clinical ... trial showed the benefit of the 12 mg/kg dose of the antibody-drug conjugate (ADC) that the companies recently took forward into phase 3.

Decipher mRNA Score for Prediction of Survival Benefit from Docetaxel at Start of Androgen Deprivation Therapy for Advanced Prostate Cancer: An Ancillary Study of the STAMPEDE Docetaxel Trials Ruth ...

AbbVie (ABBV) announced the final analysis of the confirmatory Phase 3 MIRASOL trial evaluating the efficacy and safety of ELAHERE in women ...

SESAUA annual meeting featured a prostate cancer session and a presentation by Dr. Paul Sieber discussing a post hoc analysis ...